Your Search Returned 101 tagged news reports
US Food and Drug Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a
These grants were made possible through a grant from Onyx Pharmaceuticals, an Amgen subsidiary, to scientifically evaluate and define clinical effectiveness of carfilzomib and oprozomib in non-Hodgkin lymphomas. ORP is to improve cancer care by
Topics The logo of Swiss pharmaceutical company Roche is seen at a plant in the central Swiss village of Rotkreuz November 6, 2013. Roche's newly approved leukemia drug Gazyva helped patients live nearly a year longer without the disease worsening
Gazyva is a new monoclonal antibody designed to attach to CD20, a protein found only on B-cells, and it works by helping certain immune system cells to attack cancer cells. The drug is claimed to be the first to receive the FDA's breakthrough therapy
Swiss drugmaker Roche Holding AG has reported a 6 percent increase in overall sales for the first nine months of 2012, based on demand for its cancer drugs. The Basel, Switzerland-based company says its group sales over three quarters rose to 34.9
Gilead Sciences Inc. stock continued to climb Thursday after the company stopped a study of an experimental leukemia treatment because patients had substantially improved. Phase III study of its chronic lymphocytic leukemia drug, called idelalisib,
US Food and Drug Administration (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen,
Until recently, transplants between people with different blood groups were impossible. With kidney transplants, not only did the blood group have to match, but the tissue type, too. If the blood types did not match, the organ would be rejected.
The Brazilian subsidiary will produce monoclonal innovative trastuzumab, pegylated interferon against rheumatoid arthritis and rituximab to combat hepatitis type C. Biocad Brazil CEO David Zylbergeld said the State of Parana is the leading contender
ITN TrialShare, a clinical trial data and analysis portal that provides open, unprecedented access to clinical trial data, analyses and specimens.